Genentech Presented Data for Ten Medicines
This year at the American Society of Hematology (ASH) Annual Meeting, Genentech presented data for ten medicines in more than 75 abstracts [press release] including results for:
- VenclextaTM (venetoclax): Phase III data showing the chemotherapy-free, fixed-duration combination of Venclexta plus with Rituxan reduced the risk of disease worsening or death (progression-free survival; PFS, as assessed by investigator) by 83 percent compared to Rituxan plus bendamustine (BR), a standard of care, in people with previously treated chronic lymphocytic leukemia [press release].
- Polatuzumab vedotin: Phase II data demonstrating the investigational anti-CD79b antibody-drug conjugate, polatuzumab vedotin, in combination with BR increased complete response rates from 15% to 40% compared to BR alone in people with previously treated DLBCL [press release].
For additional Genentech perspective, visit the Hematology hub on gene.com.
